Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript

We including those measures in the observational study. And third, as you’ve seen in the back of the eye in geographic atrophy, there are analogous or corresponding ways to directly visualize the corneal endothelium in patients using specialized microscopy. And so, we’ll be including those measures as well. And that will give us a variety of tools to examine the characteristics of the patients and the disease progression.

Operator: Thank you. I’m showing no further questions in the queue at this time. I would now like to turn the call back over to Mr. Pratik Shah for any closing remarks.

Pratik Shah : Thank you everyone for joining us on today’s call. We look forward to updating you as we continue to make exciting progress at Design.

Operator: Thank you all for participating. This concludes today’s program. You may now disconnect.